Pneumococcal Vaccines

WASHINGTON — Delaying methotrexate initiation for 1 month after pneumococcal vaccination improves humoral response in patients with rheumatoid arthritis, according to data presented at ACR Convergence 2024.

NEW YORK — In this video from the Infectious Diseases in Children Symposium, David W. Kimberlin, MD, provides an overview of the topics that were added to the 2024-2027 Red Book published earlier this year.

A CDC advisory committee on Wednesday recommended that adults aged 65 years or older and anyone who is at least moderately immunocompromised receive a second dose of COVID-19 vaccine this season.

The CDC on Thursday recommended updated COVID-19 vaccines for the 2024-2025 respiratory season, and a newly approved 21-valent pneumococcal conjugate vaccine for adults.

NEW YORK — In this video from the Infectious Diseases in Children Symposium, Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, discusses the importance of pediatricians adopting new pneumococcal vaccines into practice to optimize patient coverage.

There have been some reports of necrosis at the injection site following receipt of the 23-valent pneumococcal vaccine, but the vaccine’s overall benefit-risk balance “remains favorable,” researchers wrote in JAMA Internal Medicine.

Over the last decade, there have been several updates to pneumococcal vaccinations in adolescents and adults, often leading to confusion among health care providers.

Over the past several years, adult pneumococcal vaccine recommendations have evolved based on the development of new vaccines.

The FDA has accepted for priority review a supplemental biologics license application for Pfizer’s 20-valent pneumococcal conjugate vaccine for use in infants and children aged 6 weeks to 17 years, Pfizer announced.

There was plenty of FDA news this year not related to COVID-19.